高亲和性 T 细胞受体用于过继细胞转移。
High-affinity T cell receptors for adoptive cell transfer.
机构信息
Department of Biomedical Engineering.
Department of Pathology, Medicine and Oncology, and.
出版信息
J Clin Invest. 2019 Jan 2;129(1):69-71. doi: 10.1172/JCI125471. Epub 2018 Dec 10.
Abstract
Adoptive cell transfer (ACT) of engineered T cell receptors (TCRs) for cancer immunotherapy has evolved from simple gene transfer of isolated TCRs to various affinity enhancement techniques that overcome limitations imposed by central and peripheral tolerance on TCR affinity. In the current issue of the JCI, Poncette et al. used mice with human TCRαβ and HLA gene loci to discover CD4+ TCRs of optimal affinity for cancer testis antigen (CTA) NY-ESO-1. They combined this TCR with a previously discovered NY-ESO-1-specific CD8+ TCR in an ACT fibrosarcoma tumor model to demonstrate the importance of T cell help in mediating antitumor responses.
摘要
过继细胞转移 (ACT) 的工程 T 细胞受体 (TCRs) 用于癌症免疫治疗，已经从简单的 TCR 分离基因转移发展到各种亲和力增强技术，克服了 TCR 亲和力受到中枢和外周耐受的限制。在本期 JCI 中，Poncette 等人利用具有人类 TCRαβ 和 HLA 基因座的小鼠，发现了对癌症睾丸抗原 (CTA) NY-ESO-1 具有最佳亲和力的 CD4+ TCR。他们将这种 TCR 与之前发现的 NY-ESO-1 特异性 CD8+ TCR 结合，在 ACT 纤维肉瘤肿瘤模型中证明了 T 细胞辅助在介导抗肿瘤反应中的重要性。
相似文献
1
High-affinity T cell receptors for adoptive cell transfer.高亲和性 T 细胞受体用于过继细胞转移。
J Clin Invest. 2019 Jan 2;129(1):69-71. doi: 10.1172/JCI125471. Epub 2018 Dec 10.
2
Effective NY-ESO-1-specific MHC II-restricted T cell receptors from antigen-negative hosts enhance tumor regression.来自抗原阴性宿主的有效的 NY-ESO-1 特异性 MHC II 限制性 T 细胞受体可增强肿瘤消退。
J Clin Invest. 2019 Jan 2;129(1):324-335. doi: 10.1172/JCI120391. Epub 2018 Dec 10.
3
Primary human lymphocytes transduced with NY-ESO-1 antigen-specific TCR genes recognize and kill diverse human tumor cell lines.用NY-ESO-1抗原特异性TCR基因转导的原代人淋巴细胞可识别并杀伤多种人类肿瘤细胞系。
J Immunol. 2005 Apr 1;174(7):4415-23. doi: 10.4049/jimmunol.174.7.4415.
4
Identification of human T-cell receptors with optimal affinity to cancer antigens using antigen-negative humanized mice.利用抗原阴性人源化小鼠鉴定对癌症抗原具有最佳亲和力的人 T 细胞受体。
Nat Biotechnol. 2015 Apr;33(4):402-7. doi: 10.1038/nbt.3147. Epub 2015 Mar 16.
5
NY-ESO-1-specific redirected T cells with endogenous TCR knockdown mediate tumor response and cytokine release syndrome.NY-ESO-1 特异性重定向 T 细胞与内源性 TCR 敲低介导肿瘤反应和细胞因子释放综合征。
J Immunother Cancer. 2022 Jun;10(6). doi: 10.1136/jitc-2021-003811.
6
NY-ESO-1 TCR single edited stem and central memory T cells to treat multiple myeloma without graft-versus-host disease.NY-ESO-1 TCR 单编辑干细胞和中央记忆 T 细胞治疗多发性骨髓瘤而无移植物抗宿主病。
Blood. 2017 Aug 3;130(5):606-618. doi: 10.1182/blood-2016-08-732636. Epub 2017 Jun 21.
7
Blockade of Programmed Death 1 Augments the Ability of Human T Cells Engineered to Target NY-ESO-1 to Control Tumor Growth after Adoptive Transfer.程序性死亡蛋白1的阻断增强了经工程改造靶向NY-ESO-1的人T细胞在过继转移后控制肿瘤生长的能力。
Clin Cancer Res. 2016 Jan 15;22(2):436-47. doi: 10.1158/1078-0432.CCR-15-1070. Epub 2015 Aug 31.
8
Allorestricted T lymphocytes with a high avidity T-cell receptor towards NY-ESO-1 have potent anti-tumor activity.对NY-ESO-1具有高亲和力T细胞受体的全限制性T淋巴细胞具有强大的抗肿瘤活性。
Int J Cancer. 2009 Aug 1;125(3):649-55. doi: 10.1002/ijc.24414.
9
Human effector T cells derived from central memory cells rather than CD8(+)T cells modified by tumor-specific TCR gene transfer possess superior traits for adoptive immunotherapy.源自中央记忆细胞而非经肿瘤特异性 TCR 基因修饰的 CD8(+)T 细胞的人类效应 T 细胞，具有用于过继免疫治疗的优越特性。
Cancer Lett. 2013 Oct 10;339(2):195-207. doi: 10.1016/j.canlet.2013.06.009. Epub 2013 Jun 18.
10
A pilot trial using lymphocytes genetically engineered with an NY-ESO-1-reactive T-cell receptor: long-term follow-up and correlates with response.一项使用经NY-ESO-1反应性T细胞受体基因工程改造的淋巴细胞的试点试验：长期随访及与反应的相关性。
Clin Cancer Res. 2015 Mar 1;21(5):1019-27. doi: 10.1158/1078-0432.CCR-14-2708. Epub 2014 Dec 23.
引用本文的文献
1
IL-7 Immunotherapies: Current Applications and Engineering Opportunities.白细胞介素-7免疫疗法：当前应用与工程学机遇
Immunol Invest. 2025 Jul;54(5):604-622. doi: 10.1080/08820139.2025.2464055. Epub 2025 Feb 21.
2
Tuning T cell receptor sensitivity through catch bond engineering.通过捕获键工程来调节 T 细胞受体的敏感性。
Science. 2022 Apr 8;376(6589):eabl5282. doi: 10.1126/science.abl5282.
3
Identification of NY-ESO-1 Specific Murine T Cell Receptors With Distinct Recognition Pattern for Tumor Immunotherapy.鉴定具有独特识别肿瘤免疫治疗模式的 NY-ESO-1 特异性鼠 T 细胞受体。
Front Immunol. 2021 Mar 23;12:644520. doi: 10.3389/fimmu.2021.644520. eCollection 2021.
本文引用的文献
1
Effective NY-ESO-1-specific MHC II-restricted T cell receptors from antigen-negative hosts enhance tumor regression.来自抗原阴性宿主的有效的 NY-ESO-1 特异性 MHC II 限制性 T 细胞受体可增强肿瘤消退。
J Clin Invest. 2019 Jan 2;129(1):324-335. doi: 10.1172/JCI120391. Epub 2018 Dec 10.
2
Adoptive cell therapy with CD4 T helper 1 cells and CD8 cytotoxic T cells enhances complete rejection of an established tumour, leading to generation of endogenous memory responses to non-targeted tumour epitopes.采用CD4辅助性T细胞1和CD8细胞毒性T细胞进行过继性细胞治疗可增强对已形成肿瘤的完全排斥，从而产生针对非靶向肿瘤表位的内源性记忆反应。
Clin Transl Immunology. 2017 Oct 20;6(10):e160. doi: 10.1038/cti.2017.37. eCollection 2017 Oct.
3
Human TCR-MHC coevolution after divergence from mice includes increased nontemplate-encoded CDR3 diversity.与小鼠分化后人类TCR-MHC的共同进化包括非模板编码的CDR3多样性增加。
J Exp Med. 2017 Nov 6;214(11):3417-3433. doi: 10.1084/jem.20161784. Epub 2017 Aug 23.
4
Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer.个体化 RNA 突变疫苗可动员针对癌症的多特异性治疗性免疫。
Nature. 2017 Jul 13;547(7662):222-226. doi: 10.1038/nature23003. Epub 2017 Jul 5.
5
Enrichment and Expansion with Nanoscale Artificial Antigen Presenting Cells for Adoptive Immunotherapy.用于过继性免疫治疗的纳米级人工抗原呈递细胞的富集与扩增
ACS Nano. 2015 Jul 28;9(7):6861-71. doi: 10.1021/acsnano.5b02829. Epub 2015 Jul 14.
6
Mutant MHC class II epitopes drive therapeutic immune responses to cancer.突变的MHC II类表位驱动针对癌症的治疗性免疫反应。
Nature. 2015 Apr 30;520(7549):692-6. doi: 10.1038/nature14426. Epub 2015 Apr 22.
7
Identification of human T-cell receptors with optimal affinity to cancer antigens using antigen-negative humanized mice.利用抗原阴性人源化小鼠鉴定对癌症抗原具有最佳亲和力的人 T 细胞受体。
Nat Biotechnol. 2015 Apr;33(4):402-7. doi: 10.1038/nbt.3147. Epub 2015 Mar 16.
8
A novel murine T-cell receptor targeting NY-ESO-1.一种靶向 NY-ESO-1 的新型鼠 T 细胞受体。
J Immunother. 2014 Apr;37(3):135-46. doi: 10.1097/CJI.0000000000000019.
9
Cancer regression and neurological toxicity following anti-MAGE-A3 TCR gene therapy.抗 MAGE-A3 TCR 基因治疗后的癌症消退和神经毒性。
J Immunother. 2013 Feb;36(2):133-51. doi: 10.1097/CJI.0b013e3182829903.
10
Development of human anti-murine T-cell receptor antibodies in both responding and nonresponding patients enrolled in TCR gene therapy trials.在 TCR 基因治疗试验中，入组的有反应和无反应患者均会产生人抗鼠 T 细胞受体抗体。
Clin Cancer Res. 2010 Dec 1;16(23):5852-61. doi: 10.1158/1078-0432.CCR-10-1280.
Zotero 插件